Unstable NarrativeClément Menviel← FREN

The line your customers keep writing you

"I don't recognise
myself anymore."

You wrote it yourselves, in your own reviews. It is already your strongest piece of creative, and it isn't an ad yet.

Thesis

The category splits itself into forty-eight symptoms. She is only living one thing.

01The market

Numbers that decide something, not numbers that decorate.

0.0million

women over 45 concerned in France — one in every two.

Rist Report · April 2025

0.0%

of women aged 45 to 60 on hormone therapy in 2025, down from around fifty per cent in the early 2000s.

ANSM · EPI-PHARE · June 2026

0%

report at least one symptom after their periods stop. Twenty to twenty-five per cent live it as severe.

Inserm · GEMVI

0

women enter menopause every year in France. An entire generation, every twelve months.

Inserm · French Senate 2023

The number that decides everything isn't how many women are concerned — it's the flip side. More than ninety-five per cent of women aged 45 to 60 go through menopause without hormone therapy. This isn't a niche waiting to be conquered; it is the French default, and it has a specific history. The American Women's Health Initiative study, in the early 2000s, collapsed prescriptions in France as it did everywhere else. Uptake has been ticking back up since 2022 — twenty-four per cent in three years — but it hasn't changed the order of magnitude.

Which means the non-hormonal market doesn't exist because some brand invented it. It exists because an entire generation of women was left without an answer for twenty years, and learned to figure it out alone. That experience — twenty years of quietly working it out on your own — is what should set the brand's tone, not any single symptom.

02The competition

What nobody in the category owns.

I read this category the way you read a pharmacy shelf: not looking for who sells the most, but for the space nobody stands in. That space is empty, and it is large.

Block A · France, pharmacy and heritage

Sérélys

Positioning

Cytoplasmic pollen extracts, no oestrogenic activity. Evidence first, story second: fifteen studies, ten of them clinical.

Strength

Pharmacist trust, seniority, prescriber recommendation.

Weak spot

Cold brand, no voice, barely on social. Sells a molecule, not an experience.

Ménocia

Positioning

One SKU per symptom, all the way to libido. Voted best pharma product 2025.

Strength

Names the taboo, product by product. Real willingness to go there.

Weak spot

Fragments the woman into symptoms. No overarching promise.

Manhaé

Positioning

The widest pharmacy range in the segment.

Strength

Shelf presence, easy for the pharmacist to explain.

Weak spot

A shelf brand, not a territory. Nothing to fall in love with.

Phyto Soya

Positioning

Legacy phytotherapy, everyday naturalness, accessible price.

Strength

Awareness, mass distribution.

Weak spot

Dated image, no modernity in the voice.

Léro · Oenobiol

Positioning

Generalist nutraceutical with a menopause SKU among many others.

Strength

Distribution.

Weak spot

Menopause is just one line in the catalogue.

Block B · France, women-led and digital-native

Omum

Positioning

Holistic hormonal-cycle beauty, from first period to menopause. Ecocert organic, in-and-out approach, skincare and supplements.

Strength

Range coherence, right aesthetic, ten years of seniority, made in France.

Weak spot

Menopause is one stage among many. Structurally cannot become the menopause brand.

Omena

Positioning

App and coaching journey, six pillars, expert content and medical endorsement. Recommends third-party products.

Strength

Editorial authority, SEO, trust.

Weak spot

No strong own product. Sells content to a market that wants relief.

Block C · International benchmark

Bonafide (US)

Non-hormonal, medical-grade, doctor-first, subscription and telehealth. Twelve to fifteen per cent of the specialist US market. Acquired for $425M by Pharmavite, then rolled out into 1,800+ Target stores.

The exact path üma can follow in Europe: clinical proof first, physical distribution second. The valuation proves the category is an asset, not a fad.

Womaness (US)

"Menopause, Meet Your Match." Pop tone, ownership and modernity, a private community called The After Party.

The cultural-permission route. Strong on awareness, thin on proof.

Equelle (Pharmavite)

A single mechanistic claim: S-equol.

The proof turned into the product name.

O Positiv · Perelel · Olly

Segmentation by stage and by symptom — gummies, bundles, subscriptions.

The entire global category is fragmenting. That's the underlying wave, and that's the opening.

Competitive synthesis

The whole category is fragmenting. Every player is slicing menopause into finer and finer symptoms and selling one product per slice. üma sells the opposite: one formula for forty-eight symptoms— a refusal, on the record, to slice the woman.

It's the only genuinely defensible edge the brand has, and it hasn't been said out loud yet. It isn't a product argument, it's a philosophical one: no woman lives forty-eight symptoms. She lives one thing — the loss of familiarity with herself — and forty-eight ways it shows up.

üma's product architecture matches lived experience exactly. No competitor can say that. Which means the creative territory and the product architecture end up saying the same sentence. That is the definition of a brand that holds.

03Personas

Drawn from the reviews, not from a workshop.

These five profiles didn't come out of a socio-demographic segmentation. They came out of reading üma's public reviews and the available literature. Each is defined by where she is in the journey, because it's the moment — not age, not income — that decides what stops the thumb.

P1

Nathalie

47

she doesn't know yet that this is what it is

Situation
Undiagnosed perimenopause. Irregular cycles, new anxiety, insomnia, mental fog. She's been told it's stress, tiredness, sometimes offered an antidepressant.
What she's looking for
A name. Not a product, a name. She wants to understand what's happening to her.
Purchase trigger
The moment someone names precisely what she's going through.
Barrier
She doesn't think the word menopause applies to her — she associates it with her mother.
Strategic role
The most underserved persona on the market and the most profitable one, because diagnosis is the trigger and she has ten years of lifetime value ahead of her.
Angle
The vocabulary of diagnosis, never of relief.

P2

Sylvie

52

the exhausted sceptic

Situation
Full menopause, long-standing severe symptoms. Has tried everything. No hormone therapy — by choice, by contraindication, or because no one ever offered it.
What she's looking for
Proof — and above all, not one more promise.
Trigger
Mechanism of action, the study, the duration, the dosage, where the actives come from.
Barrier
Fatigue. She has been let down before and she'll tell you so.
Strategic role
üma's current core, and the source of every existing review.
Angle
Proof as the hook; restraint as the signal of seriousness.

P3

Corinne

55

the high performer, quietly masking it

Situation
Senior executive, often at the peak of her career. Hot flushes in meetings, the word that won't come, sleep in pieces. Says nothing at work.
What she's looking for
To function — not to feel good. The difference matters.
Trigger
Discretion, reliability, being able to get through her day.
Barrier
Anything that sounds like wellness, letting go, or soft sisterhood.
Strategic role
High purchasing power, higher basket, and a completely open territory since no brand talks about work.
Angle
Performance and control, never softness.

P4

Hélène

61

post-menopausal

Situation
Vasomotor symptoms have eased; the concerns are now joints, bones, skin, hair, intimate health.
What she's looking for
Longevity. Prevention, continuity, autonomy.
Trigger
Long-term logic and range coherence.
Strategic role
Retention, lifetime value, cross-sell into joints, collagen, intimate comfort.
Angle
Continuity and loyalty to the body — never catching up.

P5

The witness

secondary persona

he doesn't live the symptoms, he sees them

Situation
The partner, the daughter, the colleague, the pharmacist. Often the first to notice something has shifted.
Strategic role
Opens gifting, pharmacist recommendation, and a fresh angle bank for when first-person voice gets tired.
Angle
The outside gaze as social proof — as long as the woman always gets the last word.
04Verbatims

Their words, not ours.

Everything that follows is pulled from üma's public reviews. Nothing was invented. These are the exact words women use to describe what's happening to them, and they're infinitely better than anything a copywriter could put in their mouths.

The brand currently sits at 4.7 out of 5 on more than 13,000 reviews. That isn't a satisfaction metric. It is the largest untapped hook mine in the French category.

  • "my fan had become my best friend"

    The object

    The survival prop describes the symptom better than the symptom does.

  • "I'd swing from euphoria to tears"

    The swing

    It isn't the mood, it's the distance between two moods.

  • "my partner tells me I'm smiling again"

    The third party

    Proof from someone else — so it lands as credible.

  • "thirteen years of hot flushes"

    The duration

    A number turns discomfort into injustice.

  • "no jittery feeling"

    The refusal

    She defines what she wants by what she has rejected.

  • "I was really sceptical, I'd tried it all"

    The fatigue

    Scepticism is an asset, not an obstacle.

  • "waking up less at night"

    The measure

    She's counting. So we can speak to her in numbers.

  • "I had to stop hormone therapy"

    The break

    The exact moment she becomes a prospect.

Method · Turning a verbatim into a piece of creative

A verbatim isn't a quote to drop into a carousel. It's raw material to break down. Five extractors are enough, and they apply to any review.

The object.
What the symptom made her buy, keep or move. The fan, the second pyjama, the desk fan, the towel on the pillow. The object is visual, it's true, and other women recognise it instantly.
The time.
A symptom placed in time becomes a scene. 3:14 a.m. beats "sleep issues" every time.
The third party.
What someone else noticed. It's the only kind of social proof a sceptical woman will still accept.
The number.
Thirteen years, two weeks, half of it. A number lets you assert something without ever turning it into a health claim.
The shame.
What she never told anyone. That's where the strongest hooks in the category live, and where the compliance rigour has to be tightest.

Thirteen thousand reviews aren't a reassurance asset. They are a brief engine.

05The insight

The insight is already yours.

"I don't recognise myself anymore."

What she doesn't say

She doesn't say she's in pain. She doesn't say she's getting older. Not a single symptom appears in the sentence — and yet it's the sentence every one of them says.

The verb

Recognise means identify. It also means own as yours. Both meanings work at once. She no longer identifies with the woman in the mirror, and she refuses to accept that woman as herself.

The conclusion

Menopause isn't lived as an illness. It's lived as an identity theft. Someone else has moved into the body, and she has to keep pretending it's still her.

No one in the category owns this territory, because you have to give up the promise to stand in it. That is precisely why it's available, and precisely why it will last twelve months when a symptom territory lasts three.

06Doctrine

Four principles, held.

01

Describe. Don't promise.

By forty-five, she has heard every promise beauty, nutrition and health can make. The promise doesn't stop her scroll anymore. Accuracy does. The hook that wins isn't the one that announces the best outcome — it's the one that names something she's been living without ever seeing it written down.

02

The detail that can't be faked

Not "trouble sleeping," but 3:14 a.m., every night, and the mental maths on the hours she's got left before the alarm. The test on every hook before we shoot: could a copywriter who has never spoken to a customer have written this? If yes, we bin it.

03

Regulation is our unfair advantage

Health-claim rules stop us promising the result. Which forces us to describe what she's living. And describing what she's living is exactly what converts on this audience. Our competitors treat the rule like an amputation. We treat it as a method.

04

Premium is defended in the frame, not in the brand book

Volume doesn't dilute a brand — sloppiness does. Something shot on a phone in a kitchen stays premium if what's said is exact. Here, luxury is a matter of accuracy, not production value.

07Territories

Four ways in, one voice.

T1

The takeover

Someone else is living in my body

"On the inside, I'm still thirty-four. It's the rest of me that isn't keeping up."

The gap between what she feels and what the mirror hands back. Not decline — a desynchronisation. An identity territory, so a long one: it doesn't wear out, because it isn't propped up by any single symptom.

Formats
Face-to-camera UGC without music, typographic statics, testimonial advertorial
Duration
12+ months
Target persona
P1, P2
Risk
Pathos — held in check by a total ban on sad music.
T2

The inventory

What no one ever told her

"Forty-eight symptoms. You've been told about four."

Frozen shoulders, dry eyes, tinnitus, sudden anger, a change in her own scent, the word that vanishes mid-sentence. The category is milking four symptoms and ignoring forty-four. That's both the deepest volume reserve on the market and the direct translation of üma's product promise.

Formats
Serialised UGC, carousels, educational advertorial, video lists
Duration
6 to 9 months, ~40-hook reserve
Target persona
P1, P4
Risk
The claims line. Every symptom cleared before shooting, never after.
T3

The proof

Our clinical study as the main character

"We aren't asking you to believe us. We're showing you the protocol."

üma owns its own clinical study while the category borrows other people's science. That's a difference in kind, not in degree. Proof becomes the hook itself — the only answer that lands with a woman who's had it with promises, and the only language a pharmacy will hear.

Formats
Number-led statics, protocol video, scientific spokesperson, pharmacy support
Duration
Always-on, low volume, foundation role
Target persona
P2, P3
Risk
Coldness — fixed by always pairing it with a customer voice.
T4

The witnesses

She lives it alone. Others see it.

"My mother never said a word. I'm not going to do that to my daughter."

Daughters, partners, colleagues, pharmacists. A second audience — so a second full inventory when the first one tires, and a direct lever for gifting and recommendation. Open in month four, not before, so as not to dilute T1.

Formats
Two-voice UGC, dialogue video, Mother's Day seasonality
Duration
Opens month 4, 6-month reserve
Target persona
P5
Risk
Taking her voice away. She always gets the last line of the film.
08The film

I don't recognise myself anymore.

60 s · customer VO · cutdowns 6 s, 15 s, 30 s, 60 s · Meta · TikTok · YouTube

  1. 01

    A fifty-one-year-old woman, three-quarter angle, morning light, an ordinary bathroom. She isn't doing her hair. She's looking at herself. No music.

    I don't recognise myself anymore.

  2. 02

    An alarm clock reads 3:14. Her hand doesn't turn it off. She just waits.

    They told me about hot flushes. They didn't tell me about 3:14 in the morning, every night, counting how many hours I've got left before the alarm.

  3. 03

    A meeting. She reaches for a word. Two seconds too long. She smiles it off. Nobody says anything, everyone saw.

    They didn't tell me about the word that won't come, and the second where everyone waits.

  4. 04

    Her daughter, twenty, still in the doorway. She doesn't say anything. She just looks.

    They didn't tell me about the anger that flares over a door left open — and the shame that lands right after.

  5. 05

    She folds a jumper she won't wear again and puts it away. A calm gesture, no drama, no glance to camera.

    Nobody told me it would take this long, or that I'd be sorting it out on my own.

  6. 06

    Two full seconds of silence. She leaves the bathroom. Corridor. The light shifts temperature.

    Silence. Nothing is said here — and this is the shot that turns the film.

  7. 07

    She reads. A patient leaflet, a study, a screen. She understands something and her face tightens with focus, not relief.

    So I stopped waiting to be told. I started understanding what my body was doing. Not fighting it. Understanding it.

  8. 08

    She walks outside, briskly, wide shot, in the city. She isn't radiant. She's occupied.

    I haven't gone back to being who I was.

  9. 09

    She stops. To camera. One second, no more.

    I don't recognise myself anymore. And for a while now, that hasn't been a complaint.

üma · understand your body, find yourself again.

Why this film wins · a mechanical read

Three seconds.
The hook isn't a promise, it's a sentence she has already said out loud herself. The thumb stops on recognition, never on spectacle. It's the only stopping mechanism that survives the advertising saturation of a fifty-year-old woman.
Zero claims.
The film makes no health assertion, no product benefit, no before-and-after. It walks through the regulatory frame without a single point of friction and stays a complete brand film. The constraint didn't cost us anything — it wrote the film.
The product shows up after the decision.
The pivot isn't a product, it's a decision. The brand steps into her life at the moment she takes her hand back — never at the moment she's complaining.
The loop.
The last line repeats the first word for word and flips its meaning. The film closes on itself, which drives memory without repeating the brand name and makes the 6-second cut possible.
The risk, on purpose.
"I haven't gone back to being who I was" openly refuses the going-back promise that the whole category sells. That sentence is what separates üma from its competitors — and it's the one a committee will want to cut.
What we test.
The film is a territory check, not a stand-alone piece. It generates nine testable hooks, four durations and two alternative endings. In three weeks we know if the territory holds, and why.
09The hook bank

Twelve lines, ready to start an argument.

01
"On the inside, I'm still thirty-four. It's the rest of me that isn't keeping up."

Mismatch

Face-to-camera UGC

02
"3:14 a.m. Every night."

Precision

Typographic static

03
"Nobody warned me my shoulders would hurt."

Off-inventory

UGC

04
"I don't want to be who I was again. I just want to sleep."

Counter-move

UGC

05
"My mother never said a word. I'm not doing that to my daughter."

Handing down

Two-voice UGC

06
"I cried at a yoghurt ad. I'm forty-nine."

Confession

UGC

07
"The word won't come. Everyone's waiting."

Lived scene

Short video

08
"They offered me an antidepressant. I wasn't depressed."

Medical injustice

Advertorial

Regulatory sign-off
09
"Forty-eight symptoms. You've heard about four."

Number

Static, carousel

10
"My husband understood before I did."

Witness

UGC

11
"I'm not tired. I'm exhausted. It isn't the same word."

Lexical precision

Static, UGC

12
"My scent has changed. Nobody ever talks about that."

Taboo

UGC

Regulatory sign-off

Hooks 08 and 12 are the two strongest in the set — and the two that need a regulatory and editorial call before anything moves. I'd never put them into production without sign-off, and I'd never stop suggesting them. That's the job: bring the material that starts the argument, and bring the version that clears the room in the same breath.

10The system

Winning, separated from luck.

Raise the win rate without confusing it with luck

Every piece of creative is broken down into five independent variables. Only one moves at a time, against a control. The filename carries the code — so the weekly performance read becomes a read of variables, not a ranking of thumbnails.

T1 · I03 · H02 · F04 · P01

Territory · Insight · Hook · Form · Proof

The insight library isn't a document — it's a living base. Each entry carries its source, its status, its lineage and its number of tests. An unsourced hunch doesn't get in. An insight that has produced two winners becomes an axis; an axis that has produced three winners becomes a territory.

One last point — the one that costs creative teams the most: hook fatigue and territory fatigue are not the same thing. The first is measured in days, the second in months. Almost everyone buries a territory when only its hook was worn out — and loses six months of reserve doing it.

Sources

  1. 01Rist mission report on menopause, April 2025, cited by the French National Order of Pharmacists. 17.3 million women over 45 concerned, 20–25% severe symptoms, 2.5% on hormone therapy in metropolitan France in 2024.
  2. 02ANSM and EPI-PHARE, June 2026. 496,245 women on hormone therapy in 2025, 4.4% of women aged 45–60, up 24% between 2022 and 2025, versus 6.6% in 2012.
  3. 03Inserm, dossier on the safety of hormone therapy, 2023, and the Elisa study of 5,000 women aged 50–65. 87% of women report at least one symptom; uptake was around 50% in the early 2000s.
  4. 04French Senate, women's rights delegation report on women's health at work, June 2023. 14 million women concerned, 500,000 new each year; a woman will spend on average a third of her life in the menopausal period.
  5. 05OpinionWay for Astellas Pharma France, May 2025, 1,000+ women. 87% affected at work, 93% never told their manager, 9% took sick leave, 2% received any workplace support, 52% heard sexist remarks.
  6. 06Dares. 57.3% of women aged 55–64 are in employment in France.
  7. 07Trustpilot and Judge.me, public pages of Laboratoires üma, umawell.fr. 4.7/5 across 13,000+ reviews; customer verbatims cited.
  8. 08Laboratoires üma official site, umawell.fr. Harmonie Daily, twelve actives, forty-eight symptoms, hormone-free formulation.
  9. 09Le Moniteur des pharmacies, March 2025, dossier on the segmentation of the menopause market in pharmacy.
  10. 10Businesswire, November 2023. Pharmavite acquires Bonafide Health for $425M. NutraIngredients, September 2025, Bonafide rolls out into 1,800+ Target stores.
  11. 11NutraIngredients, April 2026, on symptom- and stage-based segmentation in menopause supplement launches.
  12. 12Glossy, on Womaness and US menopause brand positioning.
  13. 13Spherical Insights, French menopause market estimated at $838.7M by 2035, 5.58% CAGR. Publisher estimate — treat as order of magnitude.

Verbatims are drawn from public customer reviews and reproduced for analysis. Any advertising reuse requires prior verification and permission. Market figures from private publishers are flagged as such.